Navigation Links
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Date:7/20/2009

EAST HANOVER, N.J., July 21 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Tekturna HCT((R)) (aliskiren and hydrochlorothiazide) tablets as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals. Tekturna HCT is a single-pill combination of Tekturna((R)) (aliskiren), the first and only approved direct renin inhibitor, and the diuretic hydrochlorothiazide (HCTZ), one of the most commonly-used high blood pressure medications.

The FDA approval of Tekturna HCT as initial therapy was based on clinical trial data involving more than 2,700 patients, which showed that treatment with the combination of Tekturna and HCTZ offered greater blood pressure reductions than either drug alone.

"Up to 85% of patients will need more than one medication to reach their blood pressure goals," said Alan Gradman, MD, Cardiologist at The Western Pennsylvania Hospital and Professor of Medicine at Temple University. "This approval gives doctors the opportunity to aggressively treat their patients with a single-pill combination of the only approved drug, Tekturna, that works by directly targeting renin and decreasing the activity of the renin angiotensin aldosterone system (RAAS) and, HCTZ, a diuretic. This results in more significant blood pressure reductions, compared to taking either drug alone."

Hypertension affects nearly 74 million US adults and is a major risk factor for cardiovascular disease, the number one leading cause of death in the US. If left untreated, patients with high blood pressure are at risk for cardiovascular events such as stroke, heart attack and heart failure. Of US adults being treated, an estimated 36% are not at their blood pressure goals.

Current US treatment guidelines support the first-line use of combination therapy in appropriate high blood pr
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 UBM Medica US announces that  ... to help oncologists and other clinicians gain a better ... of targeted therapies and immunotherapies, discusses some of the ... Every September, Blood Cancer Awareness Month ... about blood cancers—helping to increase survival rates and improve ...
(Date:9/19/2014)... 19, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ... received and approved all parts required to build ... begun to manufacture the new PCT-based instrument system.  ... ready for shipment by mid-October and that additional ... a rate of about one per week thereafter.  ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... CHADDS FORD, Pa., Oct. 22 Endo Pharmaceuticals (Nasdaq: ... and Company 21st Annual Healthcare Conference on Tuesday, November 2, 2010, ... Endo, will review the company,s products and development programs. ... from Endo,s website at www.endo.com under the investors section. ...
... Pharmaxis (ASX: PXS) today announced significant results of pooled ... III trials of Bronchitol (inhaled mannitol) in people with ... presented for the first time at the North American ... addition, more results from the second trial (CF302) have ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5
(Date:9/21/2014)... AstraZeneca’s Pulmicort is an ICS ... is used prophylactically for the maintenance treatment of ... budesonide, is an anti-inflammatory corticosteroid with a high ... includes the Pulmicort Flexhaler (budesonide) for adults and ... Pulmicort Respules for children between one and eight ...
(Date:9/21/2014)... than a quarter of house fires are started by ... ways. The first type of dryer fire occurs when the ... dryer fire occurs when lint builds up in the dryer vent ... malfunctioning electrical systems so if it doesn’t appear to be working ... some ways that you can prevent dryer fires. , Clean the ...
(Date:9/21/2014)... Burnaby Physiotherapists at Absolute PhysioCare & Sports ... to help them with preventative care. This is part ... will help clients understand their problem in a better ... in the healing process. With higher knowledge of their ... to facilitate the therapy that is initiated by the ...
(Date:9/21/2014)... New York (PRWEB) September 21, 2014 ... of their Risk Management Portal designed for Diocesan ... with the intent to support effective risk management ... scheduled to go live coinciding with Waldorf’s exhibition ... 21-24, 2014. , These applications were developed in ...
(Date:9/21/2014)... 2014 The asthma market saw ... it has become saturated with relatively efficacious standard ... (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and ... generic competition. However, the launch of seven novel ... therapies delivered by the next-generation inhalers will strongly ...
Breaking Medicine News(10 mins):Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4
... 7-9 in Las Vegas , ... Denver -- As part of its ... Water Works Association (AWWA), the authoritative resource on safe water, today ... , Oct. 7-9, 2009, in Las Vegas., , , , ,Debuted last ...
... comes as use of stimulant for enhanced mental function is ... -- A drug used to treat narcolepsy is increasingly being ... evidence that it also harbors the potential for abuse. , ... brain, the new study shows. , "This drug does seem ...
... Carestream Health, Inc. is a leading provider of dental and medical ... ... NY (PRWEB) March 17, 2009 -- Carestream Health, Inc., announced new ... (DR) imaging systems that provide direct digital capture of medical x-ray ...
... The Netherlands A number of updated guidelines will be ... of Urology (EAU) held in Stockholm, from 17 though 21 ... based on the extended text documents will also be available ... of clinical guidelines is one of the core activities of ...
... Ill., March 17 It happens in an instant, standing ... Vice President Joe Biden,s mother. For 92 year old ... guarding against taking a tumble is fast becoming a full ... now take added precautions to help prevent a fall and ...
... tobacco, and drug useOLYMPIA, Wash., March 17 A ... good choices about their health. Still, far too many ... behavior.The Healthy Youth Survey focuses on health risk behaviors. ... by more than 210,000 public school kids around the ...
Cached Medicine News:Health News:AWWA partners with WaterSmart Innovations conference 2Health News:Narcolepsy Drug Might Be Addictive 2Health News:Narcolepsy Drug Might Be Addictive 3Health News:Carestream Health Announces New Orders From from U.S. Healthcare Facilities For for Its Digital Radiography Solutions 2Health News:EAU launches new clinical guidelines for 2009 -- kidney cancer 2Health News:Safety Alert: From the American Academy of Orthopaedic Surgeons 2Health News:New Survey Results Give a Window Into Teen Behavior and Risks 2Health News:New Survey Results Give a Window Into Teen Behavior and Risks 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: